Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind study evaluating VX-661 (lumacaftor) in combination with Ivacaftor for cystic fibrosis; the trial completed and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• VX-661 (lumacaftor) (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-06-12